MARKET

ALVO

ALVO

Alvotech
NASDAQ
4.670
-0.250
-5.08%
After Hours: 4.670 0 0.00% 19:30 11/12 EST
OPEN
4.500
PREV CLOSE
4.920
HIGH
4.760
LOW
4.305
VOLUME
2.99M
TURNOVER
--
52 WEEK HIGH
6.53
52 WEEK LOW
2.940
MARKET CAP
1.67B
P/E (TTM)
-7.4268
1D
5D
1M
3M
1Y
5Y
1D
Alvotech Earnings Call Highlights Growth and Risks
TipRanks · 8h ago
Alvotech falls on Q3 results
Seeking Alpha · 13h ago
Alvotech Reports Nine-Month 2026 Results and Business Update
TipRanks · 18h ago
Corteva Posts Downbeat Q3 Results, Joins Nvidia, Alvotech And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Benzinga · 19h ago
Why Tetra Tech Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Benzinga · 22h ago
Alvotech Records Revenue Dip And EBITDA Rise In Q3; Manufacturing Expands In New York And Iceland
NASDAQ · 1d ago
Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 1d ago
Alvotech reports Q3 revenue $111.6M, consensus $128.4M
TipRanks · 1d ago
More
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Webull offers Alvotech SA stock information, including NASDAQ: ALVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALVO stock methods without spending real money on the virtual paper trading platform.